1. Home
  2. PPBT vs CMND Comparison

PPBT vs CMND Comparison

Compare PPBT & CMND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PPBT
  • CMND
  • Stock Information
  • Founded
  • PPBT 2010
  • CMND 2017
  • Country
  • PPBT Israel
  • CMND Canada
  • Employees
  • PPBT N/A
  • CMND N/A
  • Industry
  • PPBT Biotechnology: Pharmaceutical Preparations
  • CMND Biotechnology: Pharmaceutical Preparations
  • Sector
  • PPBT Health Care
  • CMND Health Care
  • Exchange
  • PPBT Nasdaq
  • CMND Nasdaq
  • Market Cap
  • PPBT 6.5M
  • CMND 5.2M
  • IPO Year
  • PPBT N/A
  • CMND N/A
  • Fundamental
  • Price
  • PPBT $2.27
  • CMND $0.99
  • Analyst Decision
  • PPBT Strong Buy
  • CMND
  • Analyst Count
  • PPBT 1
  • CMND 0
  • Target Price
  • PPBT $33.00
  • CMND N/A
  • AVG Volume (30 Days)
  • PPBT 286.5K
  • CMND 87.7K
  • Earning Date
  • PPBT 05-23-2025
  • CMND 06-12-2025
  • Dividend Yield
  • PPBT N/A
  • CMND N/A
  • EPS Growth
  • PPBT N/A
  • CMND N/A
  • EPS
  • PPBT N/A
  • CMND N/A
  • Revenue
  • PPBT N/A
  • CMND N/A
  • Revenue This Year
  • PPBT N/A
  • CMND N/A
  • Revenue Next Year
  • PPBT N/A
  • CMND N/A
  • P/E Ratio
  • PPBT N/A
  • CMND N/A
  • Revenue Growth
  • PPBT N/A
  • CMND N/A
  • 52 Week Low
  • PPBT $2.00
  • CMND $0.85
  • 52 Week High
  • PPBT $20.60
  • CMND $2.30
  • Technical
  • Relative Strength Index (RSI)
  • PPBT 40.43
  • CMND 47.58
  • Support Level
  • PPBT $2.18
  • CMND $0.94
  • Resistance Level
  • PPBT $2.41
  • CMND $1.05
  • Average True Range (ATR)
  • PPBT 0.20
  • CMND 0.06
  • MACD
  • PPBT -0.01
  • CMND 0.00
  • Stochastic Oscillator
  • PPBT 27.96
  • CMND 38.22

About PPBT Purple Biotech Ltd.

Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.

About CMND Clearmind Medicine Inc.

Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.

Share on Social Networks: